Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 17/20 | 0.69 |
| ▸ | TP53 | P04637 | 11/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | THRB | P10828 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328993 | 0.82 | MAPT (0.68) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL13952063 | 0.81 | MCHR1 (0.67) | HSD17B10TSHRMCHR2MCHR1 | |
| SCHEMBL8163274 | 0.81 | MCHR1 (0.67) | HSD17B10TSHRMCHR2MCHR1 | |
| SCHEMBL3324930 | 0.80 | MAPT (0.68) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL8114797 | 0.79 | MAPT (0.67) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL3320266 | 0.79 | MAPT (0.68) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL4341169 | 0.78 | MCHR1 (0.69) | HSD17B10TSHRMCHR2MCHR1 | |
| SCHEMBL3323177 | 0.78 | MAPT (0.73) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL3326670 | 0.77 | MAPT (1.00) | MAPTTP53LMNATHRBPOLB | |
| SCHEMBL3324330 | 0.77 | MAPT (0.78) | MAPTTP53LMNATHRBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | claimed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | claimed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | claimed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | claimed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2139472-B1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288432-B2 | Tetrahydroindole derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2012-10-16 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
| EP-2000176-A1 | Tetrahydroindole derivatives as NADPH Oxidase inhibitors | GenKyo Tex (CH) | 2008-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120749-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CYBB, NQO1, NOX4 | MAPT 1042/4885TP53 4124/4885LMNA 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.